On October 23, Lisin Bio announced that it had signed an investment agreement with Altolan Ventures, which operates the accelerator program 'Road to Unicorn'.
An official from Altolan Ventures said, “This investment is a recognition of the research and development achievements and new drug development capabilities that Lisin Bio has demonstrated during the coaching period,” and added, “Lisin Bio has proven its technological perfection and commercialization speed in a short period of time, and has great scalability as a synthetic biology-based platform company.”
Regarding the investment background, the official explained, “In particular, the development of next-generation super antibiotics to address the issue of antibiotic resistance and the pipeline of new oral protein drugs are technologies with global competitiveness.”
Meanwhile, Lisin Bio was selected for the 3rd Daejeon round of 'IBK Changgong', an innovative startup incubation program operated by IBK Industrial Bank of Korea.
- See more related articles
You must be logged in to post a comment.